Valuation: Atossa Therapeutics, Inc.

Market Cap 16.62M 14.59M 13.43M 12.52M 23.6M 1.58B 24.08M 162M 62.59M 776M 62.4M 61.05M 2.7B P/E 2026 *
-0.45x
P/E 2027 * -0.56x
Enterprise Value 16.62M 14.59M 13.43M 12.52M 23.6M 1.58B 24.08M 162M 62.59M 776M 62.4M 61.05M 2.7B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+2.59%
1 week+13.71%
Current month+3.10%
1 month-61.06%
3 months-61.06%
6 months-78.96%
Current year-77.52%
1 week 1.7
Extreme 1.7
2.04
1 month 1.7
Extreme 1.7
5.14
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
107.25
10 years 1.7
Extreme 1.7
891
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
12/05Free

Director

10,000 0.1161%
12/05Free

Director

10,000 0.1161%
12/05Free

Founder

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
+3.11%+13.71%-83.90%-89.80% 16.62M
+3.08%+6.47%-0.25%+6.27% 47.18B
-0.28%+9.95%+406.02%+595.75% 39.82B
+5.86%+10.06%+25.63%-7.59% 32.25B
+2.81%+5.85%+19.65%+62.20% 31.68B
+0.69%+8.72%+14.80%+30.86% 24.59B
-1.00%+11.08% - - 16.57B
+4.28%+7.59%+71.84%+130.80% 15.12B
-0.15%+2.15%+12.64%+17.55% 13.69B
-0.84%+2.46%+96.29%+90.85% 13.1B
Average +1.66%+6.79%+62.52%+92.99% 23.4B
Weighted average by Cap. +1.92%+7.41%+94.22%+137.54%

Financials

2026 *2027 *
Net sales - -
Net income -37.39M -32.83M -30.22M -28.16M -53.11M -3.56B -54.19M -363M -141M -1.75B -140M -137M -6.07B -39.31M -34.52M -31.77M -29.61M -55.83M -3.74B -56.97M -382M -148M -1.83B -148M -144M -6.38B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
02/07/26 USD 1.990 +3.11% 38,633
30/06/26 USD 1.930 -2.53% 73,951
29/06/26 USD 1.980 +5.32% 181,707
26/06/26 USD 1.880 +6.21% 377,885
25/06/26 USD 1.770 +1.14% 143,643
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.930USD
Average target price
22.00USD
Spread / Average Target
+1,039.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock